Our study demonstrates that selective COX-2 inhibition by celecoxib induces DNA damage and inhibits DNA synthesis, resulting in p53 activation and subsequent anti-proliferative effects in glioblastoma cells. Here, PTGS2 is linked to glioblastoma.